These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 11889264)

  • 1. Association study of dopamine D2, D3 receptor gene polymorphisms with motor fluctuations in PD.
    Zappia M; Annesi G; Quattrone A
    Neurology; 2002 Mar; 58(5):837; author reply 837-8. PubMed ID: 11889264
    [No Abstract]   [Full Text] [Related]  

  • 2. Dopamine D2 receptor gene polymorphism and the risk of levodopa-induced dyskinesias in PD.
    Oliveri RL; Annesi G; Zappia M; Civitelli D; Montesanti R; Branca D; Nicoletti G; Spadafora P; Pasqua AA; Cittadella R; Andreoli V; Gambardella A; Aguglia U; Quattrone A
    Neurology; 1999 Oct; 53(7):1425-30. PubMed ID: 10534246
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association study of dopamine D2, D3 receptor gene polymorphisms with motor fluctuations in PD.
    Wang J; Liu ZL; Chen B
    Neurology; 2001 Jun; 56(12):1757-9. PubMed ID: 11425949
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association study of dopamine receptor gene polymorphisms with drug-induced hallucinations in patients with idiopathic Parkinson's disease.
    Makoff AJ; Graham JM; Arranz MJ; Forsyth J; Li T; Aitchison KJ; Shaikh S; Grünewald RA
    Pharmacogenetics; 2000 Feb; 10(1):43-8. PubMed ID: 10739171
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Task-dependent interactions between dopamine D2 receptor polymorphisms and L-DOPA in patients with Parkinson's disease.
    Kwak Y; Bohnen NI; Müller ML; Dayalu P; Burke DT; Seidler RD
    Behav Brain Res; 2013 May; 245():128-36. PubMed ID: 23439215
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dopamine receptor gene polymorphisms in Parkinson's disease patients reporting "sleep attacks".
    Rissling I; Geller F; Bandmann O; Stiasny-Kolster K; Körner Y; Meindorfner C; Krüger HP; Oertel WH; Möller JC
    Mov Disord; 2004 Nov; 19(11):1279-84. PubMed ID: 15390060
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association between DRD2 and DRD3 gene polymorphisms and gastrointestinal symptoms induced by levodopa therapy in Parkinson's disease.
    Rieck M; Schumacher-Schuh AF; Altmann V; Callegari-Jacques SM; Rieder CRM; Hutz MH
    Pharmacogenomics J; 2018 Jan; 18(1):196-200. PubMed ID: 27779245
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Influence of DRD1 and DRD3 Polymorphisms in the Occurrence of Motor Effects in Patients with Sporadic Parkinson's Disease.
    Dos Santos EUD; Duarte EBC; Miranda LMR; Asano AGC; Asano NMJ; Maia MMD; de Souza PRE
    Neuromolecular Med; 2019 Sep; 21(3):295-302. PubMed ID: 31119645
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pramipexole in Parkinson's disease. A short-term study using the combined levodopa-dopamine agonist test.
    Fabbrini G; Barbanti P; Aurilia C; Pauletti C; Meco G
    Funct Neurol; 2002; 17(4):199-201. PubMed ID: 12675263
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Overexpression of D2/D3 receptors increases efficacy of ropinirole in chronically 6-OHDA-lesioned Parkinsonian rats.
    Matsukawa N; Maki M; Yasuhara T; Hara K; Yu G; Xu L; Kim KM; Morgan JC; Sethi KD; Borlongan CV
    Brain Res; 2007 Jul; 1160():113-23. PubMed ID: 17573046
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dopamine D5 receptor gene polymorphism and the risk of levodopa-induced motor fluctuations in patients with Parkinson's disease.
    Wang J; Liu ZL; Chen B
    Neurosci Lett; 2001 Jul; 308(1):21-4. PubMed ID: 11445276
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A placebo-controlled study of ropinirole, a new D2 agonist, in the treatment of motor fluctuations of L-DOPA-treated parkinsonian patients.
    Rascol O; Lees AJ; Senard JM; Pirtosek Z; Brefel C; Montastruc JL; Fuell D
    Adv Neurol; 1996; 69():531-4. PubMed ID: 8615176
    [No Abstract]   [Full Text] [Related]  

  • 13. Pathogenesis of levodopa-induced dyskinesia: focus on D1 and D3 dopamine receptors.
    Guigoni C; Aubert I; Li Q; Gurevich VV; Benovic JL; Ferry S; Mach U; Stark H; Leriche L; Håkansson K; Bioulac BH; Gross CE; Sokoloff P; Fisone G; Gurevich EV; Bloch B; Bezard E
    Parkinsonism Relat Disord; 2005 Jun; 11 Suppl 1():S25-9. PubMed ID: 15885624
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Attenuation of levodopa-induced dyskinesia by normalizing dopamine D3 receptor function.
    Bézard E; Ferry S; Mach U; Stark H; Leriche L; Boraud T; Gross C; Sokoloff P
    Nat Med; 2003 Jun; 9(6):762-7. PubMed ID: 12740572
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Improved therapies for Parkinson's disease: life beyond dopamine D2/D3 receptor agonists.
    Williams M; Wright S; Lloyd GK
    Trends Pharmacol Sci; 1997 Sep; 18(9):307-10. PubMed ID: 9345846
    [No Abstract]   [Full Text] [Related]  

  • 16. The influence of SLC6A3 and DRD2 polymorphisms on levodopa-therapy in patients with sporadic Parkinson's disease.
    Dos Santos EUD; Sampaio TF; Tenório Dos Santos AD; Bezerra Leite FC; da Silva RC; Crovella S; Asano AGC; Asano NMJ; de Souza PRE
    J Pharm Pharmacol; 2019 Feb; 71(2):206-212. PubMed ID: 30353564
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recognition and treatment of response fluctuations in Parkinson's disease: review article.
    Verhagen Metman L
    Amino Acids; 2002; 23(1-3):141-5. PubMed ID: 12373528
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dopamine D3 receptor as a therapeutic target for antipsychotic and antiparkinsonian drugs.
    Joyce JN
    Pharmacol Ther; 2001; 90(2-3):231-59. PubMed ID: 11578658
    [TBL] [Abstract][Full Text] [Related]  

  • 19. No allelic association between Parkinson's disease and dopamine D2, D3, and D4 receptor gene polymorphisms.
    Nanko S; Ueki A; Hattori M; Dai XY; Sasaki T; Fukuda R; Ikeda K; Kazamatsuri H
    Am J Med Genet; 1994 Dec; 54(4):361-4. PubMed ID: 7726209
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of the putative dopamine D1 agonist and D2 antagonist FCE 23884 on Parkinson's disease.
    Metman LV; Blanchet PJ; de Jong D; Mouradian MM; Chase TN
    Mov Disord; 1996 May; 11(3):257-60. PubMed ID: 8723141
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.